CCND1 and non-small cell lung carcinoma: MiR-134 inhibits NSCLC growth through mechanisms including targeting EGFR [75], downregulating oncogene CCND1 [76], and inhibiting epithelial-to-mesenchymal transition (EMT) by targeting FOXM1 [77].